Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and peptide forums for subcutaneous research-peptide GHK-Cu use. They are not from published trials.
Brief post-injection facial flushing
The most consistent community feedback is a warmth and visible flush in the face, neck, and upper chest within 5-15 minutes of injection, fading by 30 minutes. Users in community sources commonly describe the intensity as dose-dependent. Self-reported community sources consistently attribute this to the copper-induced vasodilatory effect rather than the GHK peptide itself.
Community sources commonly describe a brief metallic taste in the 30-60 minutes after injection. Some users self-report it as similar to chewing on a copper coin. The pattern fades by 1-2 hours.
Injection-site reactions
Community reports cluster around mild redness or itching at the subcutaneous injection site, typically lasting under 24 hours. Site rotation and bringing the reconstituted vial to room temperature are the two factors community sources most consistently describe as reducing reaction frequency.
Localized site discoloration at high-dose repeated injection
Sparse community reports describe faint bluish or brownish discoloration at sites injected repeatedly with high-dose GHK-Cu (above community-typical doses). The discoloration is attributed by community sources to copper localization in the subcutaneous tissue. It fades over weeks of rotation away from the affected site.
Less Common Events
These appear sparsely in community data.
- Headache in the first 1-2 doses — sometimes attributed by community sources to vasodilatory effects.
- Brief lightheadedness post-injection — community sources describe sitting briefly after injecting at higher doses.
- Mild nausea — rare; community sources commonly attribute it to combined GHK-Cu and other-peptide stacks rather than to GHK-Cu alone.
What Published Mechanism Research Implies (And Doesn't)
GHK-Cu's documented activities — stimulating fibroblast proliferation, modulating collagen and glycosaminoglycan synthesis, affecting gene expression at scale (Pickart & Margolina describe an effect on roughly 31% of human genes, PMID 29986520) — are mechanism findings, not adverse-event predictions. A mechanism this broad implies that user-relevant effects could emerge at high doses or long durations that have not been studied formally. No published research characterizes adverse events at sustained injectable doses above 5-10 mg/week in humans.
Wilson's disease — autosomal recessive copper-transport defect causing copper accumulation — is the condition most often cited in community sources as a contraindication. Published GHK-Cu research does not directly evaluate Wilson's disease patients; the avoidance pattern in the community is precautionary, based on the molecule's copper content.
Users with diagnosed copper-metabolism disorders should consult a licensed physician before any use.
Dose-Response Patterns Documented by Sources
Topical research uses cosmetic concentrations (0.1-3% formulations); injectable community sources cluster around 1-5 mg per dose, 2-3x weekly. Self-reported community sources describe:
- Flushing intensity scaling with per-injection dose.
- Metallic taste duration scaling with per-injection dose.
- Site reactions independent of dose magnitude — appears at low and high doses similarly.
No published research validates these relationships. Topical research's dose-response curves do not transfer to injectable use.
Dose-Pause and Stopping Patterns
Community reports describe two patterns. Pause-and-resume — short 3-5 day breaks when site reactions persist or flushing becomes socially intrusive. Dose reduction — community sources describe halving the per-injection dose when flushing or metallic taste becomes too intrusive, then re-evaluating at 2 weeks.
There is no published guideline for when to stop GHK-Cu. Topical-use literature does not address injectable cessation.
